174 related articles for article (PubMed ID: 22640715)
1. Epithelial ovarian cancer.
Al-Niaimi AN; Ahmed M; Petersen CB
Obstet Gynecol Clin North Am; 2012 Jun; 39(2):269-83. PubMed ID: 22640715
[No Abstract] [Full Text] [Related]
2. A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women.
Leandersson P; Kalapotharakos G; Henic E; Borgfeldt H; Petzold M; Høyer-Hansen G; Borgfeldt C
Anticancer Res; 2016 Mar; 36(3):957-65. PubMed ID: 26976984
[TBL] [Abstract][Full Text] [Related]
3. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ledermann JA; Raja FA; Fotopoulou C; Gonzalez-Martin A; Colombo N; Sessa C;
Ann Oncol; 2013 Oct; 24 Suppl 6():vi24-32. PubMed ID: 24078660
[No Abstract] [Full Text] [Related]
4. Comparison of Clinical Outcomes of
Eoh KJ; Park HS; Park JS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
Cancer Res Treat; 2017 Apr; 49(2):408-415. PubMed ID: 27488874
[TBL] [Abstract][Full Text] [Related]
5. Genital Cancers in Women: Ovarian Cancer.
Kuznia AL; Roett MA
FP Essent; 2015 Nov; 438():24-30. PubMed ID: 26569048
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer: epidemiology, biology, and prognostic factors.
Holschneider CH; Berek JS
Semin Surg Oncol; 2000; 19(1):3-10. PubMed ID: 10883018
[TBL] [Abstract][Full Text] [Related]
8. BRCA1/2 mutation status is an independent factor of improved survival for advanced (stage III-IV) ovarian cancer.
Rudaitis V; Zvirblis T; Kanopiene D; Janulynaite D; Griskevicius L; Janavicius R
Int J Gynecol Cancer; 2014 Oct; 24(8):1395-400. PubMed ID: 25248112
[TBL] [Abstract][Full Text] [Related]
9. [Epithelial ovarian cancer: what is the consensus in 1995?].
Chevallier B; Dessogne P
Bull Cancer; 1995 Nov; 82(11):923-8. PubMed ID: 8535018
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer during pregnancy.
Gezginç K; Karataylı R; Yazıcı F; Acar A; Celik C; Capar M
Int J Gynaecol Obstet; 2011 Nov; 115(2):140-3. PubMed ID: 21872237
[TBL] [Abstract][Full Text] [Related]
11. The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients.
Steffensen KD; Waldstrøm M; Brandslund I; Petzold M; Jakobsen A
Int J Gynecol Cancer; 2012 Nov; 22(9):1474-82. PubMed ID: 23095772
[TBL] [Abstract][Full Text] [Related]
12. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
Sölétormos G; Duffy MJ; Othman Abu Hassan S; Verheijen RH; Tholander B; Bast RC; Gaarenstroom KN; Sturgeon CM; Bonfrer JM; Petersen PH; Troonen H; CarloTorre G; Kanty Kulpa J; Tuxen MK; Molina R
Int J Gynecol Cancer; 2016 Jan; 26(1):43-51. PubMed ID: 26588231
[TBL] [Abstract][Full Text] [Related]
13. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
Guo N; Peng Z
J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
[TBL] [Abstract][Full Text] [Related]
14. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
[TBL] [Abstract][Full Text] [Related]
15. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
[TBL] [Abstract][Full Text] [Related]
16. Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass.
Lokich E; Palisoul M; Romano N; Craig Miller M; Robison K; Stuckey A; DiSilvestro P; Mathews C; Granai CO; Lambert-Messerlian G; Moore RG
Gynecol Oncol; 2015 Nov; 139(2):248-52. PubMed ID: 26364809
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
Oncotarget; 2015 Sep; 6(29):28491-501. PubMed ID: 26143638
[TBL] [Abstract][Full Text] [Related]
18. The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.
Plotti F; Scaletta G; Capriglione S; Montera R; Luvero D; Lopez S; Gatti A; De Cicco Nardone C; Terranova C; Angioli R
Int J Gynecol Cancer; 2017 May; 27(4):696-702. PubMed ID: 28406844
[TBL] [Abstract][Full Text] [Related]
19. Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis.
Lu KH
Fam Cancer; 2008; 7(1):53-8. PubMed ID: 17636427
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Time-Varying Effect of Prognostic Factors on Survival in Ovarian Cancer.
Chang C; Chiang AJ; Wang HC; Chen WA; Chen J
Ann Surg Oncol; 2015 Nov; 22(12):3976-80. PubMed ID: 25777089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]